Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 20 | 2021 | 45 | 4.100 |
Why?
|
| Glaucoma | 9 | 2020 | 22 | 2.660 |
Why?
|
| Optic Nerve Diseases | 6 | 2020 | 19 | 2.500 |
Why?
|
| Glaucoma, Open-Angle | 6 | 2020 | 22 | 2.220 |
Why?
|
| Intraocular Pressure | 11 | 2020 | 41 | 2.120 |
Why?
|
| Retinal Ganglion Cells | 12 | 2020 | 30 | 2.100 |
Why?
|
| Nerve Fibers | 12 | 2020 | 38 | 1.870 |
Why?
|
| Optic Disk | 4 | 2020 | 11 | 1.870 |
Why?
|
| Visual Acuity | 9 | 2020 | 76 | 1.850 |
Why?
|
| Visual Fields | 12 | 2020 | 29 | 1.450 |
Why?
|
| Algorithms | 6 | 2020 | 537 | 1.250 |
Why?
|
| Vision, Low | 2 | 2018 | 4 | 1.090 |
Why?
|
| Papilledema | 2 | 2018 | 13 | 1.080 |
Why?
|
| Aged | 27 | 2021 | 10257 | 0.890 |
Why?
|
| Retrospective Studies | 18 | 2020 | 3612 | 0.880 |
Why?
|
| Cross-Sectional Studies | 15 | 2021 | 1485 | 0.840 |
Why?
|
| Bruch Membrane | 3 | 2019 | 3 | 0.820 |
Why?
|
| Male | 31 | 2021 | 19434 | 0.750 |
Why?
|
| Humans | 40 | 2021 | 32284 | 0.740 |
Why?
|
| Photography | 3 | 2019 | 42 | 0.740 |
Why?
|
| Fluorescein Angiography | 3 | 2019 | 18 | 0.730 |
Why?
|
| Middle Aged | 26 | 2021 | 11843 | 0.720 |
Why?
|
| Female | 33 | 2021 | 19954 | 0.720 |
Why?
|
| Lasers, Solid-State | 2 | 2019 | 8 | 0.700 |
Why?
|
| Eye Diseases, Hereditary | 2 | 2018 | 2 | 0.670 |
Why?
|
| Macular Degeneration | 2 | 2020 | 25 | 0.670 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 3896 | 0.620 |
Why?
|
| Retinal Vessels | 4 | 2021 | 25 | 0.620 |
Why?
|
| Iridectomy | 1 | 2019 | 1 | 0.600 |
Why?
|
| Glaucoma, Angle-Closure | 1 | 2019 | 3 | 0.600 |
Why?
|
| Iris | 1 | 2019 | 7 | 0.600 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2018 | 1 | 0.560 |
Why?
|
| Vitreous Body | 1 | 2018 | 10 | 0.560 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2018 | 2 | 0.550 |
Why?
|
| Phacoemulsification | 1 | 2018 | 5 | 0.550 |
Why?
|
| Endophthalmitis | 1 | 2018 | 8 | 0.540 |
Why?
|
| Ciliary Body | 1 | 2018 | 1 | 0.540 |
Why?
|
| Hydrophthalmos | 1 | 2018 | 1 | 0.540 |
Why?
|
| Microphthalmos | 1 | 2018 | 1 | 0.540 |
Why?
|
| Skin Abnormalities | 1 | 2018 | 1 | 0.540 |
Why?
|
| Color Vision | 1 | 2018 | 1 | 0.540 |
Why?
|
| Night Vision | 1 | 2018 | 1 | 0.540 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2017 | 1 | 0.540 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 9 | 0.540 |
Why?
|
| Ophthalmology | 1 | 2018 | 7 | 0.540 |
Why?
|
| Light | 1 | 2018 | 34 | 0.540 |
Why?
|
| Laser Coagulation | 1 | 2018 | 13 | 0.530 |
Why?
|
| Uveal Neoplasms | 1 | 2018 | 25 | 0.530 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2018 | 25 | 0.530 |
Why?
|
| Malpractice | 1 | 2018 | 20 | 0.530 |
Why?
|
| Laser Therapy | 1 | 2018 | 51 | 0.530 |
Why?
|
| Liability, Legal | 1 | 2018 | 23 | 0.530 |
Why?
|
| Endoscopy | 1 | 2018 | 54 | 0.520 |
Why?
|
| Tonometry, Ocular | 5 | 2020 | 11 | 0.520 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 100 | 0.510 |
Why?
|
| Patient Compliance | 2 | 2015 | 206 | 0.490 |
Why?
|
| Melanoma | 1 | 2018 | 166 | 0.490 |
Why?
|
| Alzheimer Disease | 4 | 2020 | 281 | 0.480 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 364 | 0.480 |
Why?
|
| Epilepsy | 2 | 2014 | 79 | 0.480 |
Why?
|
| ROC Curve | 4 | 2020 | 169 | 0.460 |
Why?
|
| Eye Diseases | 1 | 2015 | 4 | 0.450 |
Why?
|
| Appointments and Schedules | 1 | 2015 | 21 | 0.450 |
Why?
|
| Appendicitis | 1 | 2015 | 15 | 0.440 |
Why?
|
| Cumulative Trauma Disorders | 1 | 2014 | 13 | 0.430 |
Why?
|
| Sprains and Strains | 1 | 2014 | 11 | 0.420 |
Why?
|
| Microscopy, Acoustic | 3 | 2019 | 3 | 0.420 |
Why?
|
| Adult | 12 | 2020 | 9263 | 0.420 |
Why?
|
| Mammography | 1 | 2014 | 41 | 0.420 |
Why?
|
| Minority Groups | 1 | 2014 | 81 | 0.400 |
Why?
|
| Neurosurgical Procedures | 1 | 2014 | 93 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 906 | 0.400 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 167 | 0.390 |
Why?
|
| Vision Disorders | 4 | 2020 | 23 | 0.370 |
Why?
|
| Postoperative Complications | 1 | 2017 | 818 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 394 | 0.370 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 502 | 0.360 |
Why?
|
| Fundus Oculi | 4 | 2019 | 13 | 0.360 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 180 | 0.350 |
Why?
|
| Microvessels | 3 | 2021 | 30 | 0.340 |
Why?
|
| Gonioscopy | 3 | 2020 | 3 | 0.340 |
Why?
|
| Choroid | 2 | 2021 | 4 | 0.330 |
Why?
|
| Contrast Sensitivity | 2 | 2020 | 5 | 0.290 |
Why?
|
| Disease Progression | 5 | 2020 | 590 | 0.250 |
Why?
|
| Child | 3 | 2018 | 2446 | 0.240 |
Why?
|
| United States | 4 | 2020 | 4079 | 0.230 |
Why?
|
| Chronic Disease | 2 | 2018 | 411 | 0.220 |
Why?
|
| Area Under Curve | 3 | 2019 | 90 | 0.220 |
Why?
|
| Infant | 2 | 2018 | 1024 | 0.190 |
Why?
|
| Angiography | 2 | 2021 | 76 | 0.190 |
Why?
|
| Case-Control Studies | 3 | 2021 | 858 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2019 | 3410 | 0.180 |
Why?
|
| Adolescent | 4 | 2020 | 3521 | 0.180 |
Why?
|
| Heme Oxygenase-1 | 1 | 2011 | 35 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 46 | 0.160 |
Why?
|
| Autophagy | 1 | 2011 | 55 | 0.160 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 113 | 0.160 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2020 | 9 | 0.160 |
Why?
|
| Macula Lutea | 1 | 2020 | 9 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 880 | 0.160 |
Why?
|
| Artifacts | 1 | 2020 | 45 | 0.160 |
Why?
|
| Vision Tests | 1 | 2020 | 2 | 0.160 |
Why?
|
| Macrophages | 1 | 2011 | 164 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 67 | 0.150 |
Why?
|
| Parkinson Disease | 1 | 2021 | 87 | 0.150 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2019 | 2 | 0.150 |
Why?
|
| Retinal Neurons | 1 | 2019 | 4 | 0.150 |
Why?
|
| Population Surveillance | 1 | 2020 | 120 | 0.150 |
Why?
|
| Vitrectomy | 1 | 2019 | 10 | 0.150 |
Why?
|
| Geographic Atrophy | 1 | 2019 | 1 | 0.150 |
Why?
|
| Physical Examination | 1 | 2019 | 83 | 0.150 |
Why?
|
| Retinal Degeneration | 1 | 2019 | 21 | 0.140 |
Why?
|
| Registries | 1 | 2020 | 294 | 0.140 |
Why?
|
| Arteritis | 1 | 2018 | 1 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 767 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 105 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 232 | 0.140 |
Why?
|
| Risk Factors | 2 | 2017 | 3938 | 0.140 |
Why?
|
| Plasmapheresis | 1 | 2018 | 11 | 0.140 |
Why?
|
| Vancomycin | 1 | 2018 | 17 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2019 | 236 | 0.140 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2018 | 4 | 0.140 |
Why?
|
| Trisomy | 1 | 2018 | 11 | 0.130 |
Why?
|
| Chromosomes, Human, X | 1 | 2018 | 13 | 0.130 |
Why?
|
| Optic Disk Drusen | 1 | 2017 | 1 | 0.130 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 26 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2238 | 0.130 |
Why?
|
| Acute Disease | 1 | 2018 | 253 | 0.130 |
Why?
|
| Medical Errors | 1 | 2018 | 34 | 0.130 |
Why?
|
| Time Factors | 2 | 2019 | 2196 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2011 | 716 | 0.130 |
Why?
|
| Electroencephalography | 2 | 2014 | 75 | 0.130 |
Why?
|
| Cognition | 1 | 2020 | 548 | 0.120 |
Why?
|
| Reoperation | 1 | 2017 | 247 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2018 | 368 | 0.120 |
Why?
|
| Epidemiology | 1 | 2016 | 5 | 0.120 |
Why?
|
| Biostatistics | 1 | 2016 | 8 | 0.120 |
Why?
|
| Prevalence | 2 | 2020 | 960 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2016 | 99 | 0.120 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 71 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 336 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2016 | 114 | 0.110 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 75 | 0.110 |
Why?
|
| Iohexol | 1 | 2015 | 8 | 0.110 |
Why?
|
| Colitis, Ischemic | 1 | 2014 | 1 | 0.110 |
Why?
|
| Mesenteric Veins | 1 | 2014 | 10 | 0.110 |
Why?
|
| Arteriovenous Malformations | 1 | 2014 | 7 | 0.110 |
Why?
|
| Marfan Syndrome | 1 | 2014 | 5 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2018 | 329 | 0.110 |
Why?
|
| Mesenteric Arteries | 1 | 2014 | 20 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2021 | 2320 | 0.110 |
Why?
|
| Curriculum | 1 | 2016 | 203 | 0.110 |
Why?
|
| Young Adult | 3 | 2020 | 2652 | 0.100 |
Why?
|
| Incidence | 1 | 2017 | 1244 | 0.100 |
Why?
|
| Aging | 1 | 2020 | 941 | 0.100 |
Why?
|
| Contrast Media | 1 | 2015 | 136 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 8 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 555 | 0.100 |
Why?
|
| Language | 1 | 2013 | 35 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 73 | 0.090 |
Why?
|
| Brain | 1 | 2019 | 966 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 773 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2013 | 128 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2015 | 1248 | 0.080 |
Why?
|
| Ocular Hypertension | 2 | 2020 | 9 | 0.080 |
Why?
|
| Regional Blood Flow | 2 | 2021 | 84 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2019 | 554 | 0.060 |
Why?
|
| Age Factors | 2 | 2020 | 1179 | 0.050 |
Why?
|
| Fovea Centralis | 1 | 2020 | 1 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 82 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 61 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2020 | 27 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2011 | 190 | 0.040 |
Why?
|
| Autopsy | 1 | 2020 | 37 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 116 | 0.040 |
Why?
|
| Cytokines | 1 | 2011 | 236 | 0.040 |
Why?
|
| Random Allocation | 1 | 2019 | 246 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2019 | 93 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 755 | 0.030 |
Why?
|
| North Carolina | 1 | 2021 | 1299 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 760 | 0.030 |
Why?
|
| Rats | 1 | 2011 | 1892 | 0.030 |
Why?
|
| Axilla | 1 | 2016 | 18 | 0.030 |
Why?
|
| California | 1 | 2016 | 61 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2016 | 29 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 62 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2016 | 113 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 171 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2016 | 126 | 0.030 |
Why?
|
| Mice | 1 | 2011 | 2544 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 72 | 0.030 |
Why?
|
| Students, Medical | 1 | 2016 | 126 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1211 | 0.030 |
Why?
|
| Asian Americans | 1 | 2013 | 92 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 743 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 8165 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 1840 | 0.020 |
Why?
|
| Hispanic Americans | 1 | 2013 | 772 | 0.020 |
Why?
|
| African Americans | 1 | 2013 | 1335 | 0.020 |
Why?
|